Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 18, 2025Chinese Medical JournalOpen Access

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWei LiuTXTing XieZZZhuoxin Zhang

Discussion

Loading...

Member takes

Overview

Pilot trial shows efficacy and safety of CNCT19 in aggressive B-cell lymphoma, indicating promise for future treatments.

Key Points

  • CNCT19s produced an overall response rate of 75% in patients with relapsed or refractory aggressive B-cell lymphoma.
  • After 54 months, the estimated progression-free survival and overall survival rates for patients were 25% and 37.5%, respectively.
  • The treatment involved lymphodepleting chemotherapy followed by CNCT19s infusion in 16 patients with various B-cell lymphomas.
  • Cytokine release syndrome occurred in 68.8% of patients, with all cases classified as grade 1, highlighting manageable side effects.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68d433aa713b0b5dfea731e7https://doi.org/10.1097/cm9.0000000000003716
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  2. 2Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025
  3. 3Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  4. 4<scp>CD19</scp> Directed <scp>CAR</scp> T Therapy for Transformed Follicular Lymphoma: A <scp>CIBMTR</scp> Analysis2025
  5. 5BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease2025